You have full text access to this OnlineOpen article

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

  1. Taito Esaki1,*,
  2. Takashi Seto2,
  3. Hiroshi Ariyama1,
  4. Shuji Arita1,
  5. Chinatsu Fujimoto1,
  6. Koichiro Tsukasa1,
  7. Takuro Kometani2,
  8. Kaname Nosaki2,
  9. Fumihiko Hirai2,
  10. Katsuro Yagawa3

Article first published online: 7 APR 2011

DOI: 10.1111/j.1753-5174.2011.00034.x

Issue

Archives of Drug Information

Archives of Drug Information

Volume 4, Issue 2, pages 23–31, June 2011

Additional Information

How to Cite

Esaki, T., Seto, T., Ariyama, H., Arita, S., Fujimoto, C., Tsukasa, K., Kometani, T., Nosaki, K., Hirai, F. and Yagawa, K. (2011), Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Archives of Drug Information, 4: 23–31. doi: 10.1111/j.1753-5174.2011.00034.x

Author Information

  1. 1

    Departments of Gastrointestinal and Medical Oncology

  2. 2

    Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  3. 3

    AstraZeneca KK, Osaka, Japan

*Taito Esaki, MD, Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka 811-1395, Japan. Tel: (81) 92-541-3231; Fax: (81) 92-542-8503; E-mail: tesaki@nk-cc.go.jp

  1. Study type: Open label, dose escalation

  2. Study phase: Phase I

  3. Study registration number: ClinicalTrials.gov, NCT00613652

  4. Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

Publication History

  1. Issue published online: 1 JUN 2011
  2. Article first published online: 7 APR 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (591K)

References

  • 1
    Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159–69.
  • 2
    Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276–80.
  • 3
    Hedge PS, Cogswell J, Carrick J, Jackson J, Wood KW, Eng WK, et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc Am Soc Clin Oncol 2003;22:abst 535.
  • 4
    Castillo A, Morse HC, III, Godfrey VL, Naeem R, Justice MJ. Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res 2007;67:10138–47.
  • 5
    Compton DA. Spindle assembly in animal cells. Annu Rev Biochem 2000;69:95–114.
  • 6
    Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003;163:1109–16.
  • 7
    Jordan MA. Mechanisms of action of anti-tumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1–17.
  • 8
    Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001;1:370–7.
  • 9
    Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280–95.
  • 10
    Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971–4.
  • 11
    Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem 2008;8:698–704.
  • 12
    Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 2008;68:1283–95.
    Direct Link:
  • 13
    Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975–88.
  • 14
    Liu M, Yu H, Huo L, Liu J, Li M, Zhou J. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochem Pharmacol 2008;76:169–78.
  • 15
    Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 2009;69:3901–9.
  • 16
    Pinzon-Ortiz MC, Cao A, Sheehy A, Pablo L, McEachern K, Hylander-Gans L, et al. Characterization of the kinesin spindle protein inhibitor AZD4877. AACR Annual Meeting 2010;abst 4429.
  • 17
    Infante JR, Spratlin JL, Kurzrock R, Eckhardt SG, Burris HA, Pulchalski TA, et al. Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors. J Clin Oncol 2008;26(15S):abst 2501.
  • 18
    World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed October 2007).
  • 19
    Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd edition. Philadelphia, PA.: Lippincott, Williams & Wilkins; 1995.
  • 20
    Huszar D, Theoclitou ME, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009;28:197–208.
  • 21
    Knox JJ, Gill S, Synold T, Biagi JJ, Major P, Feld R, et al. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008;26:265–72.
  • 22
    Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008;26:249–55.
  • 23
    Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008;26:257–64.
  • 24
    Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, et al. A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer 2008;6:21–4.
  • 25
    Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van VP, et al. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 2008;6:103–9.
View Full Article (HTML) Get PDF (591K)